TuHURA Biosciences (HURA) Financials

Balance sheets

Sep 1, 2024Jun 1, 2024Mar 1, 2024Mar 1, 2023Mar 1, 2022

Total Assets

$4.1 M(-70.6%)$14.1 M(+143.6%)$5.8 M(-44.6%)$10.4 M-

Current Assets

$3.5 M(-74.5%)$13.6 M(+157.5%)$5.3 M(-47.6%)$10.1 M-

Non Current Assets

$657.0 K(+44.5%)$454.6 K(-7.0%)$488.8 K(+48.2%)$329.9 K-

Total Liabilities

$2.4 M(-88.4%)$21.1 M(+77.6%)$11.9 M(+261.8%)$3.3 M-

Current Liabilities

$2.3 M(-52.6%)$4.8 M(-1.7%)$4.8 M(+47.8%)$3.3 M-

Long Term Liabilities

$188.0 K(-98.8%)$16.3 M(+132.4%)$7.0 M(+100.0%)$0.0-

Shareholders Equity

$1.7 M(+124.4%)-$7.0 M(-14.7%)-$6.1 M(-184.7%)$7.2 M-

Book Value

$1.4 M(+120.3%)-$7.0 M(-14.7%)-$6.1 M(-184.9%)$7.2 M-

Working Capital

$1.2 M(-86.2%)$8.9 M(+1852.2%)$454.9 K(-93.3%)$6.8 M-

Cash And Cash Equivalents

$3.0 M(-75.5%)$12.3 M(+175.9%)$4.5 M(-54.6%)$9.8 M-

Accounts Payable

$1.9 M(+29.3%)$1.4 M(-11.5%)$1.6 M(+461.7%)$291.1 K-

Accounts Receivable

-----

Short Term Debt

-$150.7 K(+3.0%)$146.3 K(+33.0%)$110.0 K-

Long Term Debt

-$16.3 M(+132.4%)$7.0 M(+100.0%)$0.0-

Total Debt

$0.0(-100.0%)$16.4 M(+129.8%)$7.2 M(+6405.7%)$110.0 K(+100.0%)$0.0

Debt To Equity

0.0(+100.0%)-2.4(-100.0%)-1.2(-6000.0%)0.0-

Current Ratio

1.5(-46.3%)2.9(+163.3%)1.1(-64.7%)3.1-

Quick Ratio

-----

Inventory

-----

Retained Earnings

-$162.1 M(-64.4%)-$98.6 M(-5.6%)-$93.3 M(-19.8%)-$77.9 M-

PB Ratio

-----

Income statements

Sep 1, 2024Jun 1, 2024Mar 1, 2024Mar 1, 2023Mar 1, 2022

EPS

-$0.1(+59.0%)-$0.1(-8.8%)-$0.1(+74.1%)-$0.4(-777.9%)-$0.1

TTM EPS

-$0.3(-21.4%)-$0.2(-108.8%)-$0.1(+74.1%)-$0.4(-777.9%)-$0.1

Revenue

-----

TTM Revenue

-----

Total Expenses

$2.2 M(-39.0%)$3.6 M(-21.4%)$4.6 M(+81.2%)$2.5 M(+19.3%)$2.1 M

Operating Expenses

$2.2 M(-39.0%)$3.6 M(-21.4%)$4.6 M(+81.2%)$2.5 M(+19.3%)$2.1 M

Cost Of Goods Sold

-----

TTM Cost Of Goods Sold

-----

Gross Profit

-----

TTM Gross Profit

-----

Gross Margin

-----

Operating Profit

-$2.2 M(+39.0%)-$3.6 M(+21.4%)-$4.6 M(-81.2%)-$2.5 M(-19.3%)-$2.1 M

TTM Operating Profit

-$10.4 M(-26.9%)-$8.2 M(-78.6%)-$4.6 M(-81.2%)-$2.5 M(-19.3%)-$2.1 M

Operating Margin

-----

Net Income

-$2.2 M(+59.0%)-$5.3 M(-8.7%)-$4.8 M(+74.1%)-$18.7 M(-778.0%)-$2.1 M

TTM Net Income

-$12.3 M(-21.4%)-$10.1 M(-108.7%)-$4.8 M(+74.1%)-$18.7 M(-778.0%)-$2.1 M

Net Margin

-----

EBIT

-$2.2 M(+43.5%)-$3.9 M(+14.8%)-$4.6 M(+75.5%)-$18.7 M(-778.0%)-$2.1 M

TTM EBIT

-$10.7 M(-26.0%)-$8.5 M(-85.2%)-$4.6 M(+75.5%)-$18.7 M(-778.0%)-$2.1 M

EBITDA

-$2.2 M(+43.9%)-$3.9 M(+14.2%)-$4.6 M(+75.6%)-$18.6 M(-815.6%)-$2.0 M

TTM EBITDA

-$10.7 M(-25.9%)-$8.5 M(-85.8%)-$4.6 M(+75.6%)-$18.6 M(-815.6%)-$2.0 M

Selling, General & Administrative Expenses

$2.0 M(+145.9%)$795.7 K(-21.7%)$1.0 M(+10.0%)$924.2 K(+60.3%)$576.7 K

TTM SGA

$3.8 M(+108.0%)$1.8 M(+78.3%)$1.0 M(+10.0%)$924.2 K(+60.3%)$576.7 K

Depreciation And Amortization

$17.0 K(-52.3%)$35.6 K(+3.8%)$34.3 K(-43.2%)$60.4 K(-35.7%)$94.0 K

TTM D&A

$86.9 K(+24.3%)$69.9 K(+103.8%)$34.3 K(-43.2%)$60.4 K(-35.7%)$94.0 K

Interest Expense

-$1.4 M(+432.1%)$255.1 K(+100.0%)$0.0-

TTM Interest Expense

-$1.6 M(+532.1%)$255.1 K(+100.0%)$0.0-

Income Tax

-----

TTM Income Tax

-----

PE Ratio

-----

PS Ratio

-----

Cashflow statements

Sep 1, 2024Jun 1, 2024Mar 1, 2024Mar 1, 2023Mar 1, 2022

Cash From Operations

-$1.9 M(+62.7%)-$5.1 M(-32.1%)-$3.8 M(-18.6%)-$3.2 M(-74.6%)-$1.9 M

TTM CFO

-$10.8 M(-21.2%)-$8.9 M(-132.1%)-$3.8 M(-18.6%)-$3.2 M(-74.6%)-$1.9 M

Cash From Investing

--$36.5 K(-100.0%)$0.0(+100.0%)-$1.2 M(-100.0%)$0.0

TTM CFI

--$36.5 K(-100.0%)$0.0(+100.0%)-$1.2 M(-100.0%)$0.0

Cash From Financing

$0.0(-100.0%)$13.0 M(+179.7%)$4.6 M(+100.0%)$0.0(+100.0%)-$150.0 K

TTM CFF

$17.6 M(0%)$17.6 M(+279.7%)$4.6 M(+100.0%)$0.0(+100.0%)-$150.0 K

Free Cash Flow

-$1.9 M(+63.0%)-$5.1 M(-33.1%)-$3.8 M(-18.6%)-$3.2 M(-74.6%)-$1.9 M

TTM FCF

-$10.8 M(-21.1%)-$8.9 M(-133.1%)-$3.8 M(-18.6%)-$3.2 M(-74.6%)-$1.9 M

CAPEX

-----

TTM CAPEX

-----

Dividends Paid

$0.0----

TTM Dividends Paid

$0.0----

TTM Dividend Per Share

-----

TTM Dividend Yield

-----

Payout Ratio

0.0%----